Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ruxolitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01776723
What this trial is testing

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Who this might be right for
Myelomonocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute 50
Post-approval studies (Phase 4)UnknownNCT05491304
What this trial is testing

Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis

Who this might be right for
Hemophagocytic LymphohistiocytosesCytokine Storm
The Children's Hospital of Zhejiang University School of Medicine 400
Testing effectiveness (Phase 2)UnknownNCT04414098
What this trial is testing

Ruxolitinib in the Treatment of Covid-19

Who this might be right for
COVID-19
Marcelo Iastrebner 100
Testing effectiveness (Phase 2)Study completedNCT05906628
What this trial is testing

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Who this might be right for
Hand Eczema
Incyte Corporation 186
Large-scale testing (Phase 3)Study completedNCT00952289
What this trial is testing

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 309
Testing effectiveness (Phase 2)Study completedNCT02257138
What this trial is testing

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Who this might be right for
Blasts More Than 20 Percent of Bone Marrow Nucleated CellsBlasts More Than 20 Percent of Peripheral Blood White CellsMyelodysplastic/Myeloproliferative Neoplasm+2 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02742324
What this trial is testing

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

Who this might be right for
Myelofibrosis
French Innovative Leukemia Organisation 37
Large-scale testing (Phase 3)Looking for participantsNCT06479135
What this trial is testing

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPost-PV MFPost-ET Myelofibrosis+2 more
Kartos Therapeutics, Inc. 600
Testing effectiveness (Phase 2)Ended earlyNCT05123040
What this trial is testing

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Who this might be right for
Acute-graft-versus-host Disease
Masonic Cancer Center, University of Minnesota 10
Testing effectiveness (Phase 2)Looking for participantsNCT07085039
What this trial is testing

Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Who this might be right for
Castleman's Disease (CD)Idiopathic Multicentric Castleman's Disease
University of Pennsylvania 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04551131
What this trial is testing

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

Who this might be right for
Hemophagocytic Lymphohistiocytosis
St. Jude Children's Research Hospital 10
Early research (Phase 1)Looking for participantsNCT07464951
What this trial is testing

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Stephan Grupp MD PhD 30
Testing effectiveness (Phase 2)Study completedNCT02049450
What this trial is testing

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

Who this might be right for
Thalassemia Major
Novartis Pharmaceuticals 30
Testing effectiveness (Phase 2)Study completedNCT05787860
What this trial is testing

Ruxolitinib in Seborrheic Dermatitis

Who this might be right for
Seborrheic Dermatitis
Icahn School of Medicine at Mount Sinai 45
Early research (Phase 1)Looking for participantsNCT05010005
What this trial is testing

Ruxolitinib and Duvelisib in People With Lymphoma

Who this might be right for
T-cell LymphomasNK-Cell LymphomasT-cell Prolymphocytic Leukemia+1 more
Memorial Sloan Kettering Cancer Center 70
Early research (Phase 1)Looking for participantsNCT06291987
What this trial is testing

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

Who this might be right for
Myeloproliferative Neoplasms
University of Chicago 18
Early research (Phase 1)Looking for participantsNCT07548983
What this trial is testing

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Who this might be right for
Acute Myeloid Leukemia
OHSU Knight Cancer Institute 40
Testing effectiveness (Phase 2)WithdrawnNCT02973711
What this trial is testing

Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Who this might be right for
Leukemia, Chronic Myeloid
University of Michigan Rogel Cancer Center
Not applicableStudy completedNCT05421104
What this trial is testing

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Who this might be right for
Polycythemia Vera (PV)
Novartis Pharmaceuticals 1,576
Early research (Phase 1)Study completedNCT01895842
What this trial is testing

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 31
Next Page